Champions Oncology Inc (OTCMKTS:CSBR) CEO Joel Ackerman purchased 8,202 shares of the stock in a transaction on Friday, October 7th. The stock was bought at an average cost of $1.63 per share, for a total transaction of $13,369.26. Following the completion of the acquisition, the chief executive officer now owns 1,027,764 shares in the company, valued at $1,675,255.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Joel Ackerman also recently made the following trade(s):

  • On Friday, September 23rd, Joel Ackerman purchased 33 shares of Champions Oncology stock. The stock was bought at an average cost of $1.65 per share, for a total transaction of $54.45.
  • On Wednesday, September 21st, Joel Ackerman purchased 5,000 shares of Champions Oncology stock. The stock was bought at an average cost of $1.66 per share, for a total transaction of $8,300.00.

Champions Oncology Inc (OTCMKTS:CSBR) opened at 1.65 on Monday. The company’s market capitalization is $18.10 million. Champions Oncology Inc has a one year low of $1.11 and a one year high of $5.49. The stock’s 50 day moving average is $1.69 and its 200 day moving average is $2.62.

Champions Oncology (OTCMKTS:CSBR) last issued its quarterly earnings data on Friday, September 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $3.70 million for the quarter.

About Champions Oncology

Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.

Receive News & Stock Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related stocks with our FREE daily email newsletter.